Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy

Journal of the American Academy of Dermatology

Volumn 56, Issue 3, 2007, Pages 500-505

  DeWitt, Christine A ^a   Siroy, Alan E ^a   Stone, Stephen P ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPALENE; BENZOYL PEROXIDE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; ISOTRETINOIN; MINOCYCLINE; PSEUDOMONIC ACID; TETRACYCLINE; TRIAMCINOLONE;

ACNE; ADULT; ADVANCED CANCER; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CASE REPORT; COLON CANCER; COMEDO; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG HYPERSENSITIVITY; ERYTHEMA; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHOCYTIC INFILTRATION; MALE; NEUTROPHIL; PRIORITY JOURNAL; SKIN BIOPSY;

ACNE VULGARIS; ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ADULT; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; ISOTRETINOIN; LUNG NEOPLASMS; MALE; MIDDLE AGED; MINOCYCLINE; NAPHTHALENES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33847012963     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2006.06.046     Document Type: Article

References (24)

1. Salomon D.S., Brandt R., Ciardiello F., and Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19 (1995) 183-232
2. Nanney L.B., Magid M., Stoscheck C.M., and King Jr. L.E. Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages. J Invest Dermatol 83 (1984) 385-393
3. Albanell J., Rojo F., Averbuch S., Feyereislova A., Mascaro J.M., Herbst R., et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20 (2002) 110-124
4. Malik S.N., Siu L.L., Rowinsky E.K., deGraffenried L., Hammond L.A., Rizzo J., et al. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res 9 (2003) 2478-2486
5. Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Cancer 37 Suppl 4 (2001) S16-S22
6. Soulieres D., Senzer N.N., Vokes E.E., Hidalgo M., Agarwala S.S., and Siu L.L. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22 (2004) 77-85
7. Baselga J., Rischin D., Ranson M., Calvert H., Raymond E., Kieback D.G., et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20 (2002) 4292-4302
8. Perez-Soler R. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Clin Lung Cancer 6 Suppl 1 (2004) S20-S23
9. Cohen E.E., Rosen F., Stadler W.M., Recant W., Stenson K., Huo D., et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21 (2003) 1980-1987
10. Busam K.J., Capodieci P., Motzer R., Kiehn T., Phelan D., and Halpern A.C. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144 (2001) 1169-1176
11. Saltz L.B., Meropol N.J., Loehrer Sr. P.J., Needle M.N., Kopit J., and Mayer R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22 (2004) 1201-1208
12. Kris M.G., Natale R.B., Herbst R.S., Lynch Jr. T.J., Prager D., Belani C.P., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 (2003) 2149-2158
13. Perez-Soler R., Chachoua A., Hammond L.A., Rowinsky E.K., Huberman M., Karp D., et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22 (2004) 3238-3247
14. Raymond E., Faivre S., and Armand J.P. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 60 Suppl 1 (2000) 15-23 discussion 41-2
15. Woodburn J.R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82 (1999) 241-250
16. Common terminology criteria for adverse events v3.0 (CTCAE). Available at: http://ctep.cancer.gov/forms/CTCAEv3.pdf. Accessed November 30, 2006.
17. Saltz L. Epidermal growth factor receptor-negative colorectal cancer: is there truly such an entity?. Clin Colorectal Cancer 5 Suppl 2 (2005) S98-S100
18. Polyak K., Kato J.Y., Solomon M.J., Sherr C.J., Massaque J., Roberts J.M., et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 8 (1994) 9-22
19. Kimyai-Asadi A., and Jih M.H. Follicular toxic effects of chimeric anti-epidermal growth factor receptor antibody cetuximab used to treat human solid tumors. Arch Dermatol 138 (2002) 129-131
20. Monti M., Mancini L.L., Ferrari B., Rahal D., and Santoro A. Complications of therapy and a diagnostic dilemma case. Case 2. Cutaneous toxicity induced by cetuximab. J Clin Oncol 21 (2003) 4651-4653
21. Guy R., Green M.R., and Kealey T. Modeling acne in vitro. J Invest Dermatol 106 (1996) 176-182
22. Guy R., Ridden C., and Kealey T. The improved organ maintenance of the human sebaceous gland: modeling in vitro the effects of epidermal growth factor, androgens, estrogens, 13-cis retinoic acid, and phenol red. J Invest Dermatol 106 (1996) 454-460
23. Carter C.A., and Shaw B.L. Retinoic acid affects the EGF-R signaling pathway during differentiation induction of human endometrial adenocarcinoma cells. Exp Mol Pathol 68 (2000) 170-186
24. Harper R.A. Specificity in the synergism between retinoid acid and EGF on the growth of adult human skin fibroblasts. Exp Cell Res 178 (1988) 254-263